Nanome Webinar Series

Upcoming Webinars

We are working on an incredible lineup of speakers for 2023, check later or sign-up on our newsletter to be updated on upcoming webinars. 


Past Webinars

keita_2021 zoom-1

Keita Funakawa

COO at Nanome
Jonathon Gast_sq (1)

Jonathon Gast, PhD

Senior Application Scientist at Nanome
mike bishop

Mike Bishop, PhD

Drug Discovery Consultant at Nanome

Collaborative Drug Desing in XR

Recorded December 13th, 2022

How drug design and discovery can be improved across teams using XR. 

From pocket characterization to docking, and more, teams from all over the world can still come together in space through the power of XR tools

How does the day-to-day look like for scientists that use Nanome

harris headshot

Seth Harris, PhD

Director of Computational Structural Biology & Distinguished Scientist at Genentech

Exploring structural data landscapes for drug discovery:
GYST, a Genentech platform with Nanome XR integration

Recorded November 9th, 2022

Large-scale data extracts and annotations of structural features can accelerate drug discovery and research

Genentech's platform GYST creates datasets and enables their exploration by a broad range of researchers, while also provisioning information for machine learning models

Custom plugins enable seamless integration of Nanome as a visualization and analytical component in this system


Zoran Radić, PhD

Adjunct Professor at UC San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences

Virtual Reality to Aid Antidote Design:
Structure-based design to treat organophosphate poisoning

Recorded June 22nd, 2022

  Understanding spatial impaction of Novichok-inhibited acetylcholinesterase is greatly facilitated by VR

3D structures of Acetylcholinesterase help explain its catalysis and provide a template for structure-based design while revealing an unexpected paradox

Structure-based analysis aided by VR accelerates the creation and refinement of antidotes against acetylcholinesterase poisoning

brian atwood - centered

Brian Atwood, PhD

Application Scientist at Iktos

Rohit Arora, PhD

Application Scientist at Iktos

AI for the Science Metaverse:
how to accelerate drug discovery by using AI in VR

Recorded May 26th, 2022

  Iktos AI-technologies for generative chemistry and retrosynthesis planning

  Makya web application: AI for de novo drug design

Spaya web application: AI for discovering and prioritizing synthetic routes

Using Iktos tools in Nanome: a perfect place to collaborate


Andrey Kovalevsky, PhD

Senior R&D Scientist, Oak Ridge National Laboratory

Designing from "inside" the COVID-19 viral protein:
A novel chemical structure designed in VR

Recorded January 26th, 2022

Novel chemical structures for inhibiting SARS-CoV-2 replication

 VR-assisted structure-activity relationships

  Why Oak Ridge National Laboratory combines neutrons and VR for structure-based drug design

  How VR aids collaboration between structural biologists, medicinal chemists, and molecular modelers

A recording of this webinar is not available

Jackie von Salm is speaking at Nanome's next webinar

Jackie von Salm, PhD

Cofounder and CSO at Psilera Bioscience

Psychedelics & Virtual Reality: How VR aids GPCR drug discovery for a psychedelic biotech startup

Recorded Wednesday, November 17th, 2021

Why psychedelic research is so promising & what's on the horizon

Overcoming the challenges of communicating scientific research to investors

Easy ways to improve spatial awareness of chemists and the impact that brings to the lab

How Psilera is using Nanome to filter compounds

View on Demand

Wilian Cortopassi

Wilian Cortopassi

Senior Expert in Data Science at Novartis Institutes for BioMedical Research (NIBR)

The "Virtual" Reality of Drug Discovery at Novartis

Recorded Thursday, October 21st, 2021

  How Novartis is using Virtual Reality across different research sites globally (US and Switzerland)

  A case study of the main protease (Mpro) of SARS-CoV-2

  Future outlook of VR at Novartis

A recording of this webinar is not available. Click below to download our case study with Novartis instead.


Woody Sherman

Chief Computational Scientist at Roivant Discovery, former CSO at Silicon Therapeutics

The Roivant Discovery vision for physics-driven drug design and the role of virtual reality to maximize insights.

Recorded Tuesday, August 24th, 2021

  What Roivant Discovery is doing with physics-driven drug design.

 The importance of structure-based drug discovery.

  Why VR is the next step to fully realize the benefit of structure-based drug discovery for visualization, collaboration, and design.

View on Demand